Global Uterotonic Agent Market, By Drug (Carboprost, Mifepristone, Methylergonovine, Dinoprostone, Dinoprostone, Others), Indication (Postpartum Hemorrhage, Abortion, Labor, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Uterotonic Agent Market Analysis and Size
The global uterotonic agent market is expected to witness significant growth during the forecast period. The market is majorly driven by rising cases of abortion and the vulnerable women population. In addition, advances in biotechnological and pharmaceuticals sectors or industries and more collaborations are some impacting factors driving market growth. Among the different types, oxytocin is one such drug that is widely used for lactation and parturition among others.
Data Bridge Market Research analyses a growth rate in the global uterotonic agent market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Uterotonic agent, formally known as ecbolic, is a class of therapeutics that causes contractions and increases the uterine tone. Uterotonic agent helps in the treatment of postpartum or postabortion haemorrhage as well as induce labor.
Uterotonic Agent Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drug (Carboprost, Mifepristone, Methylergonovine, Dinoprostone, Dinoprostone, Others), Indication (Postpartum Hemorrhage, Abortion, Labor, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Nexus Pharmaceuticals (U.S.), Pfizer Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Corcept (U.S.), GenBioPro (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceuticals Inc (U.S.), Lupin (India), Daiichi Sankyo Company Limited (Japan), and Ferring B.V. (Switzerland)
|
|
Market Opportunities
|
|
Global Uterotonic Agent Market Dynamics
Drivers
- Surge in Abortion Rate
According to WHO, there are about 73 million abortions worldwide each year. 6 out of 10 (61%) of all unwanted pregnancies and 3 out of 10 (29%) of all pregnancies end with an abortion. Global estimates from 2010 to 2014 show that 45% of all abortions performed are unsafe. Of all unsafe abortions, one-third were performed in the least secure conditions. H. By individuals who are not trained using dangerous and invasive methods.
- Rising Childbirth Using Labor Induction
Increasing childbirth through labor induction is expected to boost the market growth over the forecast period. For instance, as per National Perinatal Information Center’s January 2019 report, induction of labor rates increased by 40% during 1997-2017 in the U.S.
Opportunities
- Rising Incidence of Postpartum Hemorrhage
Higher prevalence of postpartum hemorrhage is expected to boost the market growth. According to the study, ‘Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan’ published in the journal PLoS One in January 2019, it was witnessed that the prevalence of postpartum hemorrhage was 8.7%, and of severe postpartum hemorrhage was 2.1%. This boosts the market growth.
Restraints/Challenges
- Quality Issues
The quality issues associated with the preparation of uterotonic agents could curb the growth of the global uterotonic agent market over a forecast period.
- High Cost
The huge expenditure of these agents surely hamper the market growth.
This global uterotonic agent market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global uterotonic agent market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Uterotonic Agent Market Scope
The global uterotonic agent market is segmented on the basis of drug, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Carboprost
- Mifepristone
- Methylergonovine
- Dinoprostone
- Dinoprostone
- Others
Indication
- Postpartum Hemorrhage
- Abortion
- Labor
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Uterotonic Agent Market Regional Analysis/Insights
The global uterotonic agent market is analysed and market size insights and trends are provided by drug, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global uterotonic agent market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the established regulatory framework, rising initiatives for women’s health, rise in adoption of newer technologies and presence of refined healthcare infrastructure
Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Uterotonic Agent Market Share Analysis
The global uterotonic agent market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global uterotonic agent market
Key players operating in the global uterotonic agent market include:
- Nexus Pharmaceuticals (U.S.)
- Pfizer Inc (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Corcept (U.S.)
- GenBioPro (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceuticals Inc (U.S.)
- Lupin (India)
- Daiichi Sankyo Company Limited (Japan)
- Ferring B.V. (Switzerland)
SKU-